Introduction
In-stent restenosis is a common occurrence in the superficial femoral artery (SFA). There is no universally accepted method to treat in-stent restenosis in the SFA. It is hypothesized that using the Viabahn ePTFE covered stent to treat in-stent restenosis may prevent tissue infiltration and intimal hyperplasia that lead to restenosis.
Methods
We studied 22 patients (27 limbs) referred for treatment of severe SFA in-stent (non-Viabahn) restenosis. All patients were treated with Viabahn stent implanted in the restenotic segments. We also analyzed several demographic characteristics, and procedural and laboratory parameters that could potentially be predictors of Viabahn restenosis: age, sex, weight, blood pressure, GFR, WBC, monocyte count, lipids, presence of diabetes and chronic kidney disease, lesion lengths, and run-off score.
Methods
We studied 22 patients (27 limbs) referred for treatment of severe SFA in-stent (non-Viabahn) restenosis. All patients were treated with Viabahn stent implanted in the restenotic segments. We also analyzed several demographic characteristics, and procedural and laboratory parameters that could potentially be predictors of Viabahn restenosis: age, sex, weight, blood pressure, GFR, WBC, monocyte count, lipids, presence of diabetes and chronic kidney disease, lesion lengths, and run-off score.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
